On September 19, Moderna, Inc. fell 4.38% in regular trading, trading at $153.105 USD/share, with Turnover of $12.73 billion.

Within the Biotechnology sector where Moderna, Inc. belongs, individual stock performance was mixed. Among individual stocks, Amgen up 1.1%, Halozyme Therapeutics up 1.94%, Gilead Sciences down 0.66%, AbbVie up 0.16%, Xenon Pharmaceuticals down 31.6%.

Moderna, Inc. is a biotechnology company that discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. Its portfolio spans respiratory vaccines, latent vaccines, public health vaccines, cancer vaccines including personalized cancer and checkpoint vaccines, as well as intratumoral immuno-oncology products. The company maintains strategic collaborations with AstraZeneca, Merck, Vertex Pharmaceuticals, and other partners.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)